scholarly journals O-192. Modulation of glucose transporter 4 in an in-vitro model of decidualized human endometrial cells

1999 ◽  
Vol 14 (Suppl_3) ◽  
pp. 107-107
Author(s):  
T. Strowitzki ◽  
E. Capp
2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Claudia Perrini ◽  
Maria Giuseppina Strillacci ◽  
Alessandro Bagnato ◽  
Paola Esposti ◽  
Maria Giovanna Marini ◽  
...  

2008 ◽  
Vol 14 (5) ◽  
pp. 301-307 ◽  
Author(s):  
M.C. Ferreira ◽  
C.A. Witz ◽  
L.S. Hammes ◽  
N. Kirma ◽  
F. Petraglia ◽  
...  

2008 ◽  
Vol 592 (1-3) ◽  
pp. 13-18 ◽  
Author(s):  
Merja Bläuer ◽  
Pentti K. Heinonen ◽  
Päivi Rovio ◽  
Timo Ylikomi

2020 ◽  
Vol 318 (2) ◽  
pp. E237-E248 ◽  
Author(s):  
Heidy Cabrera-Cruz ◽  
Lorena Oróstica ◽  
Francisca Plaza-Parrochia ◽  
Ignacio Torres-Pinto ◽  
Carmen Romero ◽  
...  

Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder characterized by hyperandrogenism and ovulatory dysfunction but also obesity and hyperinsulinemia. These characteristics induce an insulin-resistant state in tissues such as the endometrium, affecting its reproductive functions. Myo-inositol (MYO) is an insulin-sensitizing compound used in PCOS patients; however, its insulin-sensitizing mechanism is unclear. To understand the relationship of MYO with insulin action in endometrial cells, sodium/myo-inositol transporter 1 (SMIT-1) (MYO-transporter), and MYO effects on protein levels related to the insulin pathway were evaluated. SMIT-1 was assessed in endometrial tissue from women with normal weight, obesity, insulin resistance, and PCOS; additionally, using an in vitro model of human endometrial cells exposed to an environment resembling hyperinsulinemic-obese-PCOS, MYO effect was evaluated on p-AMPK and GLUT-4 levels and glucose uptake by Western blot, immunocytochemistry, and confocal microscopy, respectively. SMIT-1 was detected in endometrial tissue from all groups and decreased in PCOS and obesity ( P < 0.05 vs. normal weight ). In the in vitro model, PCOS conditions decreased p-AMPK levels, while they were restored with MYO ( P < 0.05). The diminished GLUT-4 protein levels promoted by PCOS environment were restored by MYO through SMIT-1 and p-AMPK-dependent mechanism ( P < 0.05). Also, MYO restored glucose uptake in cells under PCOS condition through a p-AMPK-dependent mechanism. Finally, these results were similar to those obtained with metformin treatment in the same in vitro conditions. Consequently, MYO could be a potential insulin sensitizer through its positive effects on insulin-resistant tissues as PCOS-endometrium, acting through SMIT-1, provoking AMPK activation and elevated GLUT-4 levels and, consequently, increase glucose uptake by human endometrial cells. Therefore, MYO may be used as an effective treatment option in insulin-resistant PCOS women.


2020 ◽  
Vol 114 (3) ◽  
pp. e357
Author(s):  
Katherine E. Kostroun ◽  
Jennifer F. Knudtson ◽  
Jennifer Teague ◽  
Mubeen Sultana ◽  
Rajeshwar Rao Tekmal ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document